Abstract:
The developmentally important Notch pathway is implicated in the maintenance of cancer stem/progenitor cells in tumor hypoxia. Yet, the mechanisms that lead to Notch activation in hypoxia are not clear. AMP-activated protein kinase (AMPK), a major player in energy homeostasis, is activated by hypoxia. These considerations led us to investigate whether AMPK facilitates cancer progression through the Notch pathway under hypoxia. Our data revealed that activating AMPK through pharmacological agents or genetic approaches led to an increase in the levels of cleaved Notch1 protein, and Notch signaling, in invasive breast cancer cell lines. In contrast, inhibition or depletion of AMPK reduced cleaved Notch1 levels.
Significantly, we show that the hypoxia-induced increase in cleaved Notch1 protein levels requires AMPK activation. Furthermore, we show that AMPK modulates cleaved Notch1 protein levels by increasing its stability. Mechanistically, we identified a reduction in interaction between Notch1 and Itch/AIP4, a known ubiquitin ligase for Notch, upon AMPK activation, thus bringing about reduced degradation of cleaved Notch1. This interaction was also disrupted under hypoxia and was influenced by AMPK modulation. Further, we identified AMPK-mediated positive regulation of Fyn activity in turn regulates Itch phosphorylation and its interaction with Notch1. Finally, we observed that inhibition of AMPK under hypoxia affected self-renewal adversely, suggesting that hypoxia-induced AMPK activation might potentiate breast cancer aggressiveness through the Notch pathway.
Furthermore, high grade breast cancers that commonly show hypoxic regions revealed an association between AMPK activity and Notch signalling. Altogether, our study sheds light on context-specific oncogenic role of AMPK by reinforcing Notch1 signaling under hypoxia to facilitate breast cancer progression.
Introduction:
Developmental pathways such as Notch are known to regulate self-renewal and cell fate decisions in embryonic and tissue specific stem cells by regulating cell differentiation, survival and proliferation, whereas deregulation of Notch signaling is associated with malignant transformation (1). Accumulation of intracellular domain of Notch1, and elevated expression of Jagged1 in primary breast tumors and its correlation with poor patient survival, serve as most compelling evidence towards involvement of Notch signaling in breast cancer (2) (3) (4) . In addition, recent studies have shown reduction in mammosphere formation capability and tumor initiation upon Notch inhibition (5), highlighting the role of Notch signaling in breast cancer stem cell self-renewal.
Ligand binding results in proteolytic cleavages and the release of the Notch intracellular domain (NICD) from the plasma membrane and translocation to the nucleus. NICD forms a DNA-binding complex comprising of other co-activators like MAML, CSL, and p300 and activates target gene expression. Post-translational modifications including phosphorylation, ubiquitination, hydroxylation and acetylation affect the stability, transcriptional activity and localization of NICD. Hyper-phosphorylation at the PEST domain at the C-terminal end of NICD is responsible for ubiquitination by FbxWD7 and subsequent proteasomal degradation.
Other ubiquitin ligases such as AIP4/Itch and c-Cbl are also known to target Notch1 for degradation (6) . Together, these post translational modifications regulate the fine-tuning of half-life of Notch, and thus, its downstream signaling.
Hypoxic conditions results from an inadequate oxygen supply in solid tumor environments due to rapid cell proliferation and poor vascularisation, and is strongly associated with tumor progression, malignant spread and resistance to therapies, hindering effective cancer treatment (7) . Cellular adaptation to hypoxia is mainly orchestrated by the transcription factor Hif1-α, activating pathways such as Notch and others like, TAZ (8), CD47 (9), PHGDH (10), ALKBH5 (11) and transcription factors like Oct4, c-Myc, SOX2 which are associated with stem cell self-renewal and multipotency (12) . While Hif1-α has been shown to physically interact with NICD to augment Notch signaling, stabilization of NICD in hypoxia has also been demonstrated (13) . In spite of the importance of hypoxia in modulating Notchmediated stem cell self-renewal (14), the molecular mechanisms involved in hypoxiamediated Notch1 stabilization remain poorly understood. Hypoxia is also known to stimulate 5'-AMP-activated protein kinase (AMPK) activity (15, 16) . Previously considered to be a tumor suppressor, the role of AMPK in tumorigenesis is under debate in recent times (17) .
Reports have shown an increasing, grade-specific activation of AMPK in breast cancer patient (18) . Moreover, emerging studies as well as work from our lab highlight the role of AMPK in enabling tumor cells survive the challenges faced in the tumor microenvironment such as energy stress and matrix-deprivation (19, 20) .
Thus, although the levels of activated AMPK and activated Notch1 are reported to be high in breast cancer, and hypoxia stress which is prevalent in breast cancer is shown to activate both of these pathways, yet, a relationship between AMPK and Notch signaling has remained unexplored. In this study, we demonstrate that AMPK activation mediates stabilization of cleaved Notch1 levels through changes in Notch1 ubiquitination and degradation.
Specifically, we detected weakened interaction of Notch1 with ubiquitin ligase Itch upon AMPK activation. Finally, we show that inhibition or depletion of AMPK lowers cleaved Notch1 levels and adversely affects cancer stem cell phenotype and drug resistance under conditions of hypoxia.
Results

Cleaved Notch1 levels are elevated by activated AMPK in breast cancer cell lines:
Protein kinases have been implicated in promoting Notch signaling, however, a specific role for AMPK in the regulation of Notch pathway has not been explored. To investigate this, we treated invasive breast cancer cell line MDA-MB-231 with pharmacological activators of AMPK like A769662 and metformin. We used phosphorylation of downstream substrate ACC at Ser 79 as markers of AMPK activation. Immunoblotting using antibody that recognizes the C-terminal end of Notch1 showed an increase in cleaved Notch1 (~120 kDa) levels upon AMPK activation ( Figure 1A and Supplementary Figure 1 B ). Treatment of MDA-MB-231 cells with increasing concentrations of A769662 led to a dose-dependent increase in cleaved Notch1 levels ( Figure 1B ). There was no change in the full length protein level (300 kDa) ( Figure 1C ) or transcript level of Notch1 on A769662 treatment (Supplementary Figure 1B) , thus suggesting a possible role of post-translational modification on cleaved Notch1 upon AMPK activation. Similarly, we found elevated cleaved Notch1 levels in invasive BT 474 and HCC 1806 breast cancer cells when treated with A769662 (Supplementary Figure 1C ). However, in non-invasive MCF-7 and immortalized HMLE breast cells (21), cleaved Notch1 levels were not modulated by AMPK activation (Supplementary Figure 1C ). This suggests that the regulation of Notch1 level by AMPK could be context-specific. Since pharmacological agents can be non-specific, we additionally used genetic approaches to activate AMPK. Over expression of constitutively activated AMPK with γ R70Q mutation and a constitutively active form of AMPK upstream kinase CaMKK β in MDA-MB-231 cells showed higher level of cleaved Notch1 ( Figure 1D ). Thus, increasing AMPK activity led to elevated cleaved Notch1 levels in invasive breast cancer cells.
To further address the effects of AMPK on cleaved Notch levels, we studied the effects of AMPK inhibition and depletion. Upon treatment with Compound C, a pharmacological inhibitor of AMPK, cells showed reduced phosphorylated ACC level along with lower level of cleaved Notch1 ( Figure 1E ). To further confirm this, we used doxycycline-inducible knockdown of AMPK. In keeping with higher expression of AMPKα2 in breast cancer cell lines (20), we studied the effect of AMPK α2 knockdown in MDA-MB-231 cells stably expressing a doxycycline-inducible shAMPKα2. Induction of AMPK knockdown in MDA-MB-231 cells led to depletion of AMPK as well as led to lower level of cleaved Notch1 compared to un-induced ( Figure 1F ) or vector control cells (Supplementary Figure 1D ).
Knockdown of AMPK also led to reduced levels of cleaved Notch1 in HEK 293T cells overexpressing NICD (Supplementary Figure 1E) , additionally suggesting that the effect of AMPK on Notch may be downstream to gamma secretase cleavage. Further, AMPK α1/α2 double knockout MEFs (DKO) showed lower cleaved Notch1 levels ( Figure 1G ) which was elevated upon exogenous expression of AMPKα 1 and 2 (Supplementary Figure 1F ), further confirming an AMPK-dependent increase in cleaved Notch1 levels. These results, together, indicated that AMPK plays a positive role in regulating cleaved Notch1 levels.
We next investigated whether an increase in cleaved Notch1 levels upon AMPK activation led to higher Notch downstream signaling, we checked the levels of gamma secretasespecific cleaved Notch1 (Valine 1744) levels. We saw elevated NICD levels referred to as gamma secretase-specific cleaved Notch1 (Valine 1744) levels subsequently, by immunoblotting and immunostaining ( Figure 1H and Supplementary Figure 1G ), suggesting that the cleaved Notch1 (~120 kDa) may be active. Further, treatment with A769662 led to a 2.6-fold increase in Notch responsive 12xCSL-luciferase reporter activity ( Figure 1I ), indicative of increase in canonical Notch signaling. It also led to an increase in the levels of Hes1 and Hes5 ( Figure 1J and Supplementary Figure 1H ) -two Notch downstream effector genes. In addition, a microarray based data analysis of A769662-treated MDA-MB-231 cells further revealed upregulation of several other Notch pathway-regulated genes, such as, HES5, HEY2, SNAI2, HEYL, IFNG, CDH6 (Supplementary Figure 1I) . These results show that the elevated level of cleaved Notch1 upon AMPK activation leads to higher Notch downstream signaling.
Reduction in cleaved Notch1 levels upon AMPK inhibition under hypoxic condition:
Since hypoxia is known to increase Notch1 levels in various cancer cells (22) as well as activate AMPK (15, 16) , and our data revealed that AMPK activation leads to elevated cleaved Notch1 levels, we investigated into the requirement of AMPK in hypoxia-induced Notch1. We treated MDA-MB-231 cells with CoCl 2 , a hypoxia-mimetic, for 24 hrs. Treatment with CoCl2 led to an increase in phosphorylated AMPK levels ( Supplementary   Figure 2A ). Further, it also led to an increase in cleaved Notch1 levels (Supplementary Figure   2A ) which was inhibited in the presence of AMPK inhibitor (Figure 2A ). Similar results were seen in BT-474 cells (Supplementary Figure 2B) . Moreover, upon treatment with CoCl 2 , we did not observe changes in cleaved Notch1 level in the inducible AMPKα2 knockdown cells (sequences 1 and 4), while the control pTRIPZ expressing cells showed the expected increase in cleaved Notch1 levels ( Figure 2B and Supplementary Figure 2C ). Thus, these data suggested a role for AMPK in the hypoxia-induced increase in cleaved Notch1 levels. To further confirm these data, we used oxygen-regulatable trigas incubator. Cells cultured in 3% oxygen showed increased levels of Hif1α, carbonic anhydrase 9 (CA IX) and pAMPK (Supplementary Figure 2D -E), all of which are markers of hypoxia (15, 23) . Further, these cells also showed increase in cleaved Notch1 and gamma secretase-specific cleaved Notch1 (Valine 1744) by immunoblotting ( Supplementary Figure 2E ). In addition, we observed, increased nucleus-localized gamma secretase specific cleaved Notch1 (Valine 1744) compared to cells grown in ambient oxygen (~21%) condition ( Supplementary Fig. 2F ). Cells grown in 3% oxygen, when treated with inhibitor of AMPK ( Figure. 
AMPK inhibition during hypoxia lowers stability of cleaved Notch1:
To investigate into the mechanisms by which AMPK activation leads to higher cleaved Notch1 levels, we first checked the levels of Notch ligands Delta-like 1, 3, 4 and Jagged 1 and 2. However, we failed to find a change in the expression of Notch-ligands under AMPK activation (Supplementary Figure 3A) . Since mTOR has been associated with both positive (24) and negative (25) regulation of Notch full length receptor and transcript levels respectively, and AMPK activation leads to mTOR inhibition (20, 26), we next gauged the involvement of mTOR in the regulation of cleaved Notch1. Addition of rapamycin, an inhibitor of mTOR, failed to rescue the AMPK inhibition-mediated reduction in cleaved Notch levels (Supplementary Figure 3B ), suggesting possible mTOR-independent mechanisms of regulation of cleaved Notch1 levels downstream of AMPK activation.
We investigated if AMPK affected the stability of cleaved Notch1 using cycloheximide chase assay. Addition of cycloheximide revealed that AMPK knockdown lowers the stability of cleaved Notch1 ( Figure 3A) . Similarly, we observed reduced cleaved Notch1 stability in AMPK DKO MEFs when treated with cycloheximide (Supplementary Figure 3C) . These data suggested that the absence of AMPK enhances the rate of Notch1 degradation.
To explore if AMPK plays any role in hypoxia-induced stabilization of Notch1 (13), we grew MDA-MB-231 cells with inducible AMPK knockdown in 3% oxygen and subsequently treated with cycloheximide. Immunoblotting revealed an aggravated reduction in cleaved Notch1 levels upon AMPK knockdown ( Figure 3B ). Similarly treating MDA-MB-231 cells with CoCl 2 for 24 h along with Compound C revealed aggravated reduction in cleaved Notch1 levels on AMPK inhibition (Supplementary Figure 3D ). Since cleaved Notch1 is reported to be targeted for degradation through 26S proteasomal machinery (27), we investigated whether AMPK inhibition enhances Notch1 degradation through 26S proteasome. We found that Compound C-mediated reduction in cleaved Notch1 levels was rescued in the presence of proteasomal complex inhibitor MG132 ( Figure 3C ). Thus, AMPK activation plays a critical role in cleaved Notch1 stabilization under hypoxia and AMPK inhibition brings about an increase in cleaved Notch1 proteasomal degradation.
AMPK inhibits Notch1 ubiquitination by modulating its interaction with Itch:
To further explore the mechanism of AMPK-mediated cleaved Notch1 stability, we investigated into post-translational modifications that are known to stabilize Notch1 protein levels (6). We did not detect any alteration in the levels of serine/threonine phosphorylation or acetylation on immuno-precipitated cleaved Notch1 upon AMPK activation (Supplementary Figure 4A and Supplementary Figure 4B ). Interestingly, immunoblotting with degradation-specific K48-linked polyubiquitin antibody revealed a reduction in ubiquitinated cleaved Notch1 in A769662 treated cells ( Figure 4A ). In contrast, when we inhibited AMPK, the ubiquitinated Notch1 levels were higher (Supplementary Figure 4C) .
These data suggest that AMPK activity affects Notch1 ubiquitination levels, which possibly regulates its degradation by proteasomal pathway thereby leading to its stabilization.
Notch1 is known to be a substrate for several ubiquitin ligases such as FBXW-7, Itch/AIP4, NEDD 4, Deltex 1, c-Cbl (28). Noticeably, a recent study (29) has shown that AMPK activation disrupts the interaction of Itch/AIP4 with its substrate p73. We therefore examined a possible role for Itch in AMPK-mediated Notch1 stability. Although there was no change in Itch protein levels ( Figure 4B ), interestingly, we found that Itch interaction with Notch1 reduced on AMPK activation ( Figure 4C ). Auto-ubiquitination at K-63 linked polyubiquitin enhances the activity of Itch (30).We detected less ubiquitin smear on immuno-precipitated Itch ( Figure 4D ) indicating reduced activity of Itch under AMPK activation. Furthermore, we tested the effect of AMPK on Itch activity towards its substrates. We found that while the levels of cleaved Notch1 reduced on Itch overexpression, AMPK activation inhibited the Itch-mediated down-modulation of cleaved Notch1 ( Figure 4E ). Similar effects were observed for c-Jun, another substrate of Itch ( Figure 4E ). Overexpression of Itch in BT-474 yielded similar down-modulation of cleaved Notch1 and the same could be rescued on AMPK activation (Supplementary Figure 4D) . These results suggest a protective role for AMPK in Itch-mediated Notch degradation.
We next asked whether Itch-mediated ubiquitination is involved in cleaved Notch1 stabilization under hypoxia. Although Itch levels remained unchanged in hypoxic condition (Supplementary Figure 2F ), we observed reduced interaction of Itch with Notch1 in hypoxia, which was negated by AMPK knockdown ( Figure 4F ). Similar to our observations with 1 AMPK perturbation, we found Notch1 K-48 linked ubiquitination reduced in hypoxia and increased upon AMPK inhibition in hypoxic conditions (Supplementary Figure 4E ). Thus, these data uncover a novel AMPK-mediated regulation of Notch1 stability in hypoxia through modulating its interaction with ubiquitin ligase Itch.
To study if changes in Itch phosphorylation are involved in Notch regulation, we immunoprecipitated Itch and observed an increase in tyrosine phosphorylation of Itch in hypoxia which decreased markedly upon AMPK knockdown ( Figure 4G ). Subsequently, we probed for the levels of phospho Itch at Y420 residue and observed an increase in its levels in hypoxia; AMPK knockdown however reduced its levels ( Figure 4H ).
Phosphorylation of Itch has been shown to regulate its interaction with substrates (31). We investigated the role of Fyn which mediates inhibitory tyrosine phosphorylation of Itch leading to decrease in ubiquitination of Notch1 (31). We inhibited Fyn using Src family kinase inhibitor PP2 under condition of hypoxia and observed lower levels of cleaved Notch1 (Supplementary Figure 4F ). Further, we transfected cells with dominant negative Fyn, and found lower levels of cleaved Notch1 in hypoxia ( Figure 4I ), suggesting a possible role for Fyn in Notch1 stabilization in hypoxia. Moreover, dominant negative Fyn transfected cells had lower tyrosine phosphorylation on Itch, suggesting that Fyn-mediated regulation of Itch phosphorylation might regulate Notch1 levels in hypoxia ( Figure 4I ).
To check a possible role for AMPK in the Fyn-mediated Itch regulation, we investigated the effects of AMPK activity on Fyn. The activity of Src-family kinases (SFK), of which Fyn is a member (32), is regulated by phosphorylation at specific tyrosine residues. Since phospho-Fyn specific antibodies are not available, we used Src-family (Tyr 416) specific antibodies which detect Tyrosine 416 specific phosphorylation on Src-family members that leads to their activation (33). AMPK activation led to an increase in the levels of phosphorylated Srcfamily tyrosine 416 (Supplementary Figure 4G ). In contrast, AMPK knockdown led to a reduction in the levels of hypoxia-mediated activated SFK (Supplementary Figure 4H ). These data suggested a possible role for AMPK in positively regulating the activity of Fyn.
To further unravel the mechanisms by which AMPK augments Fyn activation, we carried out LC-MS to detect interacting proteins of Fyn in cells treated with AMPK activator A769662 and vehicle control DMSO. FLAG-tagged Fyn expressing HEK293T stable cells were immunoprecipitated with FLAG specific antibodies and protein complexes were isolated and subjected to LC-MS. PTPRF (34), a phosphatase known to dephosphorylate the inhibitory phosphorylation at Y528, was associated with Fyn only in AMPK activated condition (Table   1 ). PTPN5 (35) and PTPRC (34) are phosphatases known to dephosphorylate the activating phosphorylation of Fyn at Y416, thus decreasing its activity. These were detected in DMSO condition only (Table 2) . Our proteomic analysis further substantiated the role of AMPK in positively modulating Fyn activity, by facilitating differential association of phosphatases with Fyn. These results together indicate an important role for Fyn kinase in AMPKdependent Itch regulation in hypoxia. Together, these data identify a novel AMPK-dependent regulation of tyrosine phosphorylation of Itch by Fyn kinase in the stabilization of cleaved Notch1.
AMPK activation-mediated Notch1 stabilization leads to an increase in stem-like properties:
Since Notch signaling is implicated in cancer stem cell (CSC) maintenance (36), we asked if AMPK-mediated enhanced Notch1 stabilization is involved in this process. AMPK activation with A769662 led to an increase in the stemness-associated factors Nanog and Bmi1 which was attenuated in the presence of DAPT, a pharmacological inhibitor of Notch signaling (37), in both MDA-MB-231 ( Figure 5A ) and BT-474 cells (Supplementary Figure 5A ). To further confirm this, we abrogated Notch signaling by knocking down Notch1 in MDA-MB-231 cells using two different shRNA targeting sequences. Treatment with A769662 led to a moderate increase in Bmi1 and Nanog protein levels in control scramble cells, but not in Notch1 knockdown cells ( Figure 5B and Supplementary Figure 5B ). Moreover, the transcript levels of stemness-associated genes like Bmi1 and Sox2 increased with AMPK activation in control cells but not in Notch1 knockdown cells ( Figure 5C ). In addition, a microarray-based data analysis of A769662-treated MDA-MB-231 cells further revealed upregulation of several other stemness-related genes such as, NKAP, DLL1, NOTCH2, ERBB2, FOXC1 (data not shown). This suggests the likely involvement of Notch pathway in AMPKmediated increase in stemness in these cells. Serial sphere formation in non-adherent, serumdeprived condition serves as an in vitro mimic of stemness activity. We observed that AMPK activation with A769662 increased primary and secondary sphere formation in control cells, whereas it failed to do so in Notch1 inhibited or depleted-cells ( Figure 5D ). We next measured the CD44 high /24 low stem-like sub-population in AMPK activated cells. While treatment with A769662 led to a 2-fold increase in the CD44 high /24 low population in control cells, it failed to do so in Notch1 inhibited or depleted-cells ( Figure 5E and Supplementary Figure 5C ). These results together suggest that AMPK activation leads to elevated cancer stem cell-like properties in breast cancer cells through Notch signaling.
Hypoxia-induced AMPK activation promotes stem-like properties and drugresistance in breast cancer cells through Notch signaling:
Hypoxic condition is known to facilitate cancer stem-like properties and promote epithelial to mesenchymal transition through involvement of Notch signaling (22, 38) . Since we uncovered an important role of AMPK in modulating Notch1 levels, and thus maintenance of breast cancer stem cell population, we investigated the requirement of AMPK activation to maintain CSCs under hypoxic condition. Compared to MDA-MB-231 cells grown in 21% oxygen, cells grown in 3% oxygen showed elevated levels of Bmi1 and Nanog which was impaired on AMPK inhibition ( Figure 6A ). To further confirm this, cells were grown with hypoxia-mimetic CoCl 2 and simultaneous inhibition of AMPK brought about reduction in CoCl 2 -mediated increase in Bmi1 level (Supplementary Figure 6A ). Bmi1 and Nanog levels were also high in BT-474 cells when treated with CoCl 2 and disrupting AMPK activity brought about similar effects in presence of hypoxia (Supplementary Figure 6B ). Further, hypoxia-induced increase in sphere formation was also abrogated by AMPK inhibition ( Figure 6B ). We obtained similar results with CoCl 2 treatment in the presence of AMPK inhibition (Supplementary Figure 6C) , clearly indicating the requirement of AMPK in hypoxia-induced sphere forming potential. Next, to gauge if hypoxia-induced AMPK mediates its effects via Notch, we treated AMPK knockdown cells with synthetic Notch ligand DSL under hypoxia. We observed that the ligand-treated AMPK-knockdown cells had higher levels of cleaved Notch1, showed elevated levels of Bmi1, and also formed higher number of spheres (Figure 6Cand D) . These data suggest that hypoxia-induced AMPK activation promotes stem-like properties in breast cancer cells through Notch signaling.
Notch signalling is known to bring about increased drug resistance in hypoxic condition in various tumours such as osteosarcoma, ovarian cancer and breast cancer (39-41). Various mechanisms have been elucidated, such as increase in Sox2 levels or MRP-1 downstream of Notch1 activation upon hypoxia which helps mediate higher resistance to chemotherapeutic drugs. As we have elucidated a novel role for AMPK in hypoxia-induced increase in Notch1 signalling, therefore, we wanted to investigate whether the AMPK-mediated increase in Notch1 signalling affected drug sensitivity of breast cancer cells. We observed a 2-fold increase in the IC 50 value of doxorubicin when exposed to hypoxia and knockdown of AMPK in cells in hypoxia restored IC 50 value (Figure 6 E). DNA damage accumulated by the cells in hypoxic condition upon doxorubicin treatment was assessed by pH2A.X staining. We observed an increase in pH2A.X staining intensity upon treatment with doxorubicin ( Figure   6F ). In hypoxic condition, the cells did not accumulate DNA damage upon doxorubicin treatment, but knockdown of AMPK signalling in hypoxia led to excessive accumulation of DNA damage ( Figure 6F ) which suggests that hypoxia-induced AMPK enhances drug resistance. To gauge if hypoxia-induced AMPK indeed mediates its effects via Notch, we treated AMPK knockdown cells with synthetic Notch ligand DSL to activate Notch signalling under hypoxia and assessed the DNA damage. We observed a reduction in pH2A.X staining compared to cells without Notch activation, indicating restoration of drug resistance phenotype ( Figure 6F ). Thus, AMPK-Notch axis plays a role in mediating drug resistance in hypoxic condition.
Hypoxia-induced AMPK-Notch1 signalling in vivo
Since hypoxia conditions are prevalent in tumors (42), we validated the AMPK-Notch1 signaling axis in tumor xenografts. BT 474 cells stably expressing shRNA against AMPK α 2 were injected sub-cutaneously in immunocompromised mice; tumor formation by these cells were impaired compared to scramble control cells (20) . We found that cleaved Notch1 
Discussion
The Notch pathway, because of its importance in numerous cancers, has been a major candidate for developing therapeutic agents. While gamma secretase inhibitors and antibodies against receptor and ligands have reached clinical trials, gastrointestinal toxicity and other side effects have led to shifting of focus on therapeutic targeting of other pathways impinging on regulation of Notch signaling (43, 44) . One such pathway that we have examined is the metabolic regulator AMPK. We found AMPK to be a positive modulator of cleaved Notch1 contributing to elevated stemness and drug resistance in breast cancer cells, suggesting that inhibition of AMPK can alleviate stem-like properties, thus rendering cancer cells susceptible to existing anti-cancer agents.
Hypoxia in solid tumors is considered a malice aiding cancer progression hindering successful therapy. Both AMPK and Notch1 are activated under hypoxia, a condition prevalent during cancer progression (15, 38, 45) . Effects of hypoxia-induced Notch1 signaling have been found in, melanoma (46), adenocarcinoma of lungs (47), glioma (48), as well as breast carcinomas (22). Mechanistically, it has been shown that Hif1α and NICD directly interact and augment transcription of Notch responsive genes (13). Another mechanism implicated in this crosstalk involves FIH (factor inhibiting Hif1-α) which is critical in blocking differentiation in myogenic and neural progenitor cells (49). Moreover
Hif-1α binding to NICD also enhances proliferation and decreases differentiation in GSC (50). Hypoxia also influences breast cancer cell EMT and migration through Notch signaling,
as Hif-α synergises with Notch co-activator MAML to increase expression of Snail and Slug and reduce E-cadherin expression (51). Interestingly, Gustaffson et al., reported the stabilization and increased half-life of NICD in hypoxia, although the molecular mechanism remained unknown. Our results indicate elevated breast cancer stemness in hypoxia and further show that this is dependent on AMPK-mediated stabilization of Notch1.
Notch signalling along with a central role in self-renewal of cancer stem cells, has also been implicated in imparting resistance to therapy cancer (39-41). Recent studies have also implicated AMPK in mediating hypoxia-induced drug resistance to doxorubicin in osteosarcoma (52). Another report also implicates AMPK in mediating drug resistance to cisplatin (53). Thus, from these reports it becomes clear that inhibition of AMPK along with chemotherapy can sensitize cancer cells to chemotherapeutic agent. In this study we show that hypoxia-induced drug resistance properties are supported by AMPK activation, and this effect can be abrogated by Notch inhibition/depletion. (29). We found that interaction of cleaved Notch1
with Itch is disrupted upon AMPK activation by the regulation of Itch tyrosine phosphorylation by Fyn ( Figure 9 ). We also observed that AMPK could facilitate Fyn activation by modulating the protein tyrosine phosphatases associated with Fyn. Changes in protein phosphatase activity by LKB1 and AMPK has been previously reported in lung and cervical cancer cell lines (56) and similar changes may take place in breast cancer cells as well.
AMPK is traditionally viewed as a tumour suppressor as mTOR is negatively regulated by AMPK bringing about slower growth, and AMPK is also known to stabilize p53 bringing about cell cycle arrest (57). We did not observe transcriptional changes of Notch1 through mTOR that has been previously described (25) Interestingly, our study shows a high correlation between AMPK and Notch activation in grade 3 primary breast cancer samples that are known to contain hypoxic regions (11). In support of our observations, abundant expression of activated AMPK has also been found in human gliomas (59) (19) show in-vivo evidence of tumour promoting role of AMPK. Another study showed that this role of AMPK is evident only in a metabolically stressed tumour microenvironment context (64). Thus, our report compliments such studies on tumour promoting role of AMPK in the context of tumour hypoxia.
Inhibitory effect of metformin, which also activates AMPK, on breast cancer stem cells has been earlier reported (65). Although multiple mechanisms have been shown in this regard, these effects of metformin on cancer stem cells have been shown to be independent of AMPK (66-68). Our study revealed a novel role for AMPK in regulating hypoxia-mediated Notch1 stabilization leading to elevated stemness in breast cancer, and hence we propose that inhibition of AMPK can be a potential therapeutic strategy, alleviating self-renewal of breast cancer cells.
Materials and Methods:
Cell Culture: 0 Sphere formation assay 1x10 5 cells per 35 mm dish coated with 0.6% agar were seeded in serum-free DMEM-F12 medium with growth factors containing methylcellulose. Sphere forming efficiency was assessed by culturing these cells for 7 days with or without treatment. The primary mammospheres were counted and trypsinised and were allowed to form secondary spheres for another 7 days.
FACS analysis of surface markers
MDA-MB-231 cells and shNotch1 stables with indicated treatments, were trypsinised and 50,000 cells/tube were kept at 37º C for 1 h for surface marker recovery post trypsinisation, followed by double immunostaining with primary antibodies conjugated with FITC or PE for 45 minutes on ice. Cells were washed and resuspended in serum free medium, and analysed using BD FACS Verse. The plots were obtained using BD FACSDIVA software.
DNA damage assay
MDA-MB-231 cells were incubated with 1 µM doxorubicin at 37 C for 24 h. After quick PBS wash, cells were fixed using methanol: acetone for 5 min in -20ºC. Cells were incubated with 1:200 anti-pH2A.X antibody at 4 C, overnight and subsequently immunofluorescence was carried out. The cells were imaged at 20X and 60X using Olympus IX71. Image processing was done using Image Pro Plus and intensity of puncta was measured.
MTT assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) is a colorimetric assay that measures cell viability as a function of the redox potential of cells. Actively respiring cells can convert the water soluble MTT to insoluble purple formazan crystals.
MTT (1 mg/mL from a 5mg/mL stock) was added to the cells (in 100 µL media) at the end of the experiment and 4 h later the formazan crystals were dissolved in 100 µl of DMSO and the absorbance was measured at 570 nm in a spectrophotometer. Bangalore) approved the study. Cleaved Notch1 (Valine 1744) and pACC antibodies were used at 1/100 dilution. IHC was performed as described previously (71). Fischer's exact test was used to test the correlation between NICD and pACC.
In-vivo tumor formation BT-474 cells (1x10 6 /100 µL) were subcutaneously injected into each flank of the 10 female athymic nude mice. The mice were allowed to form tumors upto 100 mm 3 . Then the mice were randomly divided into 4 groups with 5 mice in each. DMSO was injected as a vehicle control intra-peritoneally and served as the control group. Compound C (2 mg/kg) was intraperitoneally injected into second group for every 4 days. After 24 th day the tumors were excised and fixed in 10% formalin for immunohistochemistry for NICD.
Signature gene expression
List of signature genes was taken from Molecular Signatures Database GSEA :
. 
Figure legends
